Hims & hers health, inc. (hims) - lawmakers urge crackdown on illegal weight loss drugs, novo's termination of collaboration with hims triggers securities class actions -- hagens berman

San francisco, aug. 04, 2025 (globe newswire) -- this latest development follows an announcement by novo nordisk on june 23, 2025, the danish maker of the fda-approved weight-loss medication wegovy® (a glp-1 treatment for obesity), that it terminated its collaboration with hims & hers due to concerns about its sales and “deceptive” marketing of wegovy®. novo nordisk's announcement triggered securities class action lawsuits against hims & hers health, inc. and certain of the company's executives, seeking to represent investors who purchased or otherwise acquired hims & hers securities between april 29, 2025 and june 23, 2025.
HIMS Ratings Summary
HIMS Quant Ranking